Supra-Iliac Anterior Quadratus Lumborum BlockPericapsular Nerve Group BlockAnalgesiaTotal Hip Arthroplasty
Investigational drug(s) / intervention(s)
Supra-iliac anterior quadratus lumborum blockPericapsular nerve group block
Supra-iliac anterior quadratus lumborum block: Patients will receive a supra-iliac anterior quadratus lumborum block (SA-QLB) using 20mL of bupivacaine 0.25%.
Pericapsular nerve group block: Patients will receive an ultrasound-guided pericapsular nerve group (PENG) block using 20mL of bupivacaine 0.25%.
Study summary
This study aims to compare the analgesic efficacy of supra-iliac anterior quadratus lumborum block (SA-QLB) and pericapsular nerve group (PENG) block in patients undergoing total hip arthroplasty (THA).
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
* Age from 18 to 75 years.
* Both sexes.
* American Society of Anesthesiologists (ASA) classification I-III.
* Scheduled for primary elective unilateral total hip arthroplasty (THA) under spinal anesthesia.
Exclusion Criteria:
* Known allergies to the drugs used.
* Infection at the injection site.
* Bleeding disorders.
* Recognized neuromuscular disorders.
* Opioid addiction or dependence.
* Contraindications to regional anesthesia or peripheral nerve blockade.
* Body mass index (BMI) \> 40 kg/m².
* Associated decompensated cardiac, hepatic, respiratory, or renal diseases.
Primary outcome measure(s)
Degree of pain — 12 hours postoperatively Each patient will be instructed about postoperative pain assessment with visual analog scale (VAS). VAS (0 represents "no pain" while 10 represents "the worst pain imaginable")
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.